JP2022513025A - 安定化された融合前rsv fタンパク質 - Google Patents
安定化された融合前rsv fタンパク質 Download PDFInfo
- Publication number
- JP2022513025A JP2022513025A JP2021525874A JP2021525874A JP2022513025A JP 2022513025 A JP2022513025 A JP 2022513025A JP 2021525874 A JP2021525874 A JP 2021525874A JP 2021525874 A JP2021525874 A JP 2021525874A JP 2022513025 A JP2022513025 A JP 2022513025A
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- protein
- fusion
- mutation
- rsv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 179
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 177
- 230000004927 fusion Effects 0.000 title claims abstract description 171
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims abstract description 104
- 241000725643 Respiratory syncytial virus Species 0.000 claims abstract description 95
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims abstract description 11
- 238000011282 treatment Methods 0.000 claims abstract description 6
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 230000035772 mutation Effects 0.000 claims description 174
- 229940024606 amino acid Drugs 0.000 claims description 98
- 125000000539 amino acid group Chemical group 0.000 claims description 95
- 150000001413 amino acids Chemical class 0.000 claims description 79
- 150000007523 nucleic acids Chemical class 0.000 claims description 55
- 108020004707 nucleic acids Proteins 0.000 claims description 53
- 102000039446 nucleic acids Human genes 0.000 claims description 53
- 230000000087 stabilizing effect Effects 0.000 claims description 46
- 239000013598 vector Substances 0.000 claims description 39
- 230000006798 recombination Effects 0.000 claims description 27
- 238000005215 recombination Methods 0.000 claims description 27
- 229960005486 vaccine Drugs 0.000 claims description 21
- 230000014509 gene expression Effects 0.000 claims description 19
- 230000028993 immune response Effects 0.000 claims description 15
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 9
- 229930182817 methionine Natural products 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 6
- 229960000310 isoleucine Drugs 0.000 claims description 6
- 239000013638 trimer Substances 0.000 claims description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- DMIUGJLERMOBNT-UHFFFAOYSA-N 4-amino-n-(3-methoxypyrazin-2-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound COC1=NC=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 DMIUGJLERMOBNT-UHFFFAOYSA-N 0.000 claims 1
- 230000002163 immunogen Effects 0.000 abstract description 4
- 235000018102 proteins Nutrition 0.000 description 160
- 235000001014 amino acid Nutrition 0.000 description 84
- 238000000034 method Methods 0.000 description 43
- 125000003275 alpha amino acid group Chemical group 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 35
- 108020004705 Codon Proteins 0.000 description 17
- 239000012634 fragment Substances 0.000 description 17
- 238000003860 storage Methods 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 230000003472 neutralizing effect Effects 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 108091035707 Consensus sequence Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 101710189104 Fibritin Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000034628 Celiac artery compression syndrome Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 102000004961 Furin Human genes 0.000 description 2
- 108090001126 Furin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 230000003097 anti-respiratory effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 238000000569 multi-angle light scattering Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 102220320732 rs1554306350 Human genes 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 108010087967 type I signal peptidase Proteins 0.000 description 2
- OVKKNJPJQKTXIT-JLNKQSITSA-N (5Z,8Z,11Z,14Z,17Z)-icosapentaenoylethanolamine Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO OVKKNJPJQKTXIT-JLNKQSITSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 238000012815 AlphaLISA Methods 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 108091006060 C-tagged proteins Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241001025319 Etheostoma collis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 102220534335 OX-2 membrane glycoprotein_V76G_mutation Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000711904 Pneumoviridae Species 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000144290 Sigmodon hispidus Species 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- NTGGOTYRTOXKMQ-UHFFFAOYSA-K aluminum;potassium;phosphate Chemical compound [Al+3].[K+].[O-]P([O-])([O-])=O NTGGOTYRTOXKMQ-UHFFFAOYSA-K 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- -1 carrier Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011437 continuous method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229910052743 krypton Inorganic materials 0.000 description 1
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000030500 lower respiratory tract disease Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 229960001521 motavizumab Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000005829 trimerization reaction Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
(a)46位のアミノ酸残基SのGへの変異;
(b)203位のアミノ酸残基LのIへの変異;
(c)215位のアミノ酸残基SのPへの変異
(d)357位のアミノ酸TのKへの変異;
(e)371位のアミノ酸NのYへの変異;
(f)487位のアミノ酸残基EのQ,N、又はIへの変異;
及び
(g)489位のアミノ酸残基DのYへの変異。
(a)46位のアミノ酸残基SのGへの変異;
(b)203位のアミノ酸残基LのIへの変異;
(c)215位のアミノ酸残基SのPへの変異
(d)357位のアミノ酸TのKへの変異;
(e)371位のアミノ酸NのYへの変異;
(f)487位のアミノ酸残基EのQ,N、又はIへの変異;
及び
(g)489位のアミノ酸残基DのYへの変異。
を含む方法に関する。
この安定性試験の対照として使用するRSV F配列は、サブグループAのコンセンサス配列(配列番号13)又はサブグループBのコンセンサス配列(配列番号14)のいずれかに基づいており、なぜならば、このコンセンサス配列は、臨床分離株に対応する野生型(非継代)配列に非常に類似しているからである(Kumaria et al.(2011))。検出目的のために、Fタンパク質のC末端にstrep-タグを融合させた。RSV Fでの様々な点変異の安定性を評価するために、融合前コンフォメーションのFタンパク質の含有量を、AlphaLISAで測定した。
コンセンサスRSV F(配列番号13又は14)に基づく可溶性融合前タンパク質を、明らかな不安定性(図3、4に示される)に起因して精製し得なかった。図3に示す安定化変異の一部を評価するために、既に説明されているD486N安定化変異に加えて、融合前コンフォメーションを安定化させる2つの変異(具体的には変異P101Q及びI152V)を有するRSV-Fタンパク質(RSV180305;配列番号20)を作製した(Krarup et.al.,2015)。加えて、別の安定化された融合前Fタンパク質を作製し(RSV172527;配列番号21)、この融合前Fタンパク質では、既に説明されているいくつかの安定化置換(具体的には、変異S46G、L203I、S215P、T357R、N371Y、D486N、及びD489Y)を既に含む融合前RSV Fタンパク質に、P101Q置換及びI152V置換を導入した。この構築物を、Gene Art(Life Technologies、Carlsbad,CA)で合成してコドン最適化した。この構築物を、部位特異的変異誘発及びPCRに関する分野で広く知られている標準的方法により、pCDNA2004にクローニングしたか又は生成し、配列決定した。使用する発現プラットフォームは、HEK293細胞であった。細胞を、製造業者の指示に従って293Fectin(Life Technologies)を使用して一過性にトランスフェクトし、37℃及び10%CO2で5日又は6日にわたり培養した。培養物上清を採取し、300gで5分にわたり遠心して、細胞及び細胞片を除去した。その後、0.22umの真空フィルタを使用して、遠心上清を滅菌ろ過し、使用するまで4℃で保存した。
精製されたRSV172527を、還元条件下又は非還元条件下で、4~12%(w/v)Bis-Tris NuPAGEゲル、1×MOPS(Life Technologies)で分析した。全ての手順を、製造業者の指示に従って実施した。純度分析のために、このゲルを、Krypton Infrared Protein Stain(Thermo Scientific)で染色した。非還元RSV172527及び還元RSV172527は純粋であり、F0及びF1外部ドメインそれぞれの予想される高さで、バンドが見える。
4週にわたる4℃での保存後、精製された融合前RSV Fタンパク質RSV180305、RSV172725、及び国際公開第2017/174568号パンフレットで既に説明されている対照融合前Fタンパク質(RSV150042)(配列番号22)の、融合前特異的中和抗体への結合を、ELISAで試験した。1/2 AreaPlate-96 HBプレート(白色、高タンパク質結合親和性(PerkinElmer))を、抗RSVモノクローナル抗体の試験パネルでコーティングした。Mab CR9501及びCR9502は、RSV Fの融合前コンフォメーションに特異的であり、Mab CR9506は、RSV Fの融合前コンフォメーション及び融合後コンフォメーションの両方に結合する。CR9506は、モタビズマブと競合し(データは示さない)、同一の直鎖状エピトープに結合する。これらの抗体を、1μg/mlにてPBSで希釈し、PBS中で4℃にて一晩プレートにコーティングした。翌日、プレートを洗浄緩衝液(PBS、0.05%Tween)で洗浄し、1%ウシ血清アルブミンを含むPBSでブロックした。全てのインキュベーションを、1時間にわたり室温で実施した。各工程後、プレートを洗浄緩衝液で3回洗浄した。精製されたRSV Fタンパク質の滴定液を、1%ウシ血清アルブミンを含む洗浄緩衝液で調製した。CR9506を、標準的手順に従ってビオチン化し、検出用のBM Chemiluminescence ELISA基質(POD)(Sigma Aldrich)と共に0.05μg/mlで使用した。図7に示すように、全ての精製されたRSV Fタンパク質は、融合前特異的Mab(CR9501及びCR9502)と、両方のコンフォメーションに特異的なMab(CR9506)とに同様に結合し、そのため、本発明に係るFタンパク質は融合前コンフォメーションであることが示された。
精製されたタンパク質の温度安定性を、示差走査蛍光定量法(DSF)により決定した。精製された融合前Fタンパク質を、96ウェル光学qPCRプレート内でSYPRO橙色蛍光染料(Life Technologies S6650)と混合した。最適な染料及びタンパク質の濃度を、実験により決定した(データは示さない)。タンパク質の希釈をPBSで実施し、減算参照として、染料のみを含む陰性対照サンプルを使用した。測定を、下記のパラメータを使用するqPCR機器(Applied Biosystems ViiA 7)で実施した:1秒当たり0.015℃の速度での25~95℃の温度勾配。データを、連続的に取得した。Graph Pad PRISMソフトウエア(バージョン5.04)を使用して、溶融曲線をプロットした。非線形EC50シフト方程式を使用して、最大蛍光の50%で溶融温度を算出した。RSV180305の融解温度は65.9度であり(図8a)、RSV172527の融解温度は72.9であった(図8b)。参照融合前RSV F(RSV150042)は、融解温度が65.0である(データは示さない)。
GYIPEAPRDGQAYVRKDGEWVLLSTFL
Krarup et al.,Nature Comm.6:8143,(2015)
Kumaria et al.,Virology Journal,8:372,(2011);
Letarov et al.,Biochemistry Moscow 64:817-823(1993);
McLellan,et al.Science 342,592-598(2013);
McLellan,et al.Nat Struct Mol Biol 17,248-250(2010);
McLellan,et al.Science 340,1113-1117(2013);
S-Guthe et al.,J.Mol.Biol.337:905-915.(2004).
Swanson,et al.(2011)
Claims (27)
- 1つ又は複数の安定化アミノ酸を含む組換え融合前呼吸器合胞体ウイルス(RSV)融合(F)タンパク質であって、前記1つ又は複数の安定化アミノ酸は、任意選択的に486位の安定化アミノ酸との組み合わせで、79位、101位、152位、226位、及び/又は354位に存在している、組換え融合前呼吸器合胞体ウイルス(RSV)融合(F)タンパク質。
- 前記79位のアミノ酸は、Mであり、前記101位のアミノ酸は、S、Q、若しくはTであり、前記152位のアミノ酸は、V若しくはMであり、前記226位のアミノ酸は、Mであり、及び/又は前記354位のアミノ酸は、Lであり、任意選択的に、前記486位のアミノ酸は、Nである、請求項1に記載の組換え融合前呼吸器合胞体ウイルス(RSV)融合(F)タンパク質。
- 任意選択的に486位のアミノ酸の変異との組み合わせで、79位のアミノ酸残基の変異、101位のアミノ酸残基の変異、152位のアミノ酸残基の変異、354位のアミノ酸残基の変異、及び226位のアミノ酸残基の変異からなる群から選択される1つ又は複数の安定化変異を含む請求項1又は2に記載の組換え融合前呼吸器合胞体ウイルス(RSV)融合(F)タンパク質。
- 前記79位のアミノ酸残基の変異、前記101位のアミノ酸残基の変異、前記152位のアミノ酸残基の変異、前記354位のアミノ酸残基の変異、及び前記226位のアミノ酸残基の変異からなる群から選択される1つ又は複数の安定化変異との組み合わせで、前記486位のアミノ酸残基の変異を含み、好ましくは、前記486位のアミノ酸DのNへの変異(D486N)を含む請求項3に記載の組換え融合前Fタンパク質。
- 前記79位のアミノ酸残基の変異は、アミノ酸イソロイシン(I)のメチオニン(M)への変異である、請求項3又は4に記載の組換え融合前Fタンパク質。
- 前記101位のアミノ酸残基の変異は、アミノ酸プロリン(P)のセリン(S)、グルタミン(Q)、又はトレオニン(T)への変異である、請求項3又は4に記載の組換え融合前Fタンパク質。
- 前記152位のアミノ酸残基の変異は、アミノ酸イソロイシン(I)のバリン(V)又はメチオニン(M)への変異である、請求項3又は4に記載の組換え融合前Fタンパク質。
- 前記354位のアミノ酸残基の変異は、アミノ酸グルタミン(Q)のロイシン(L)への変異である、請求項3又は4に記載の組換え融合前Fタンパク質。
- 前記226位のアミノ酸残基の変異は、アミノ酸リシン(K)のメチオニン(M)への変異である、請求項3又は4に記載の組換え融合前Fタンパク質。
- 前記組換え融合前Fタンパク質は、前記安定化変異の内の2つ以上を含む、請求項1~9のいずれか一項に記載の組換え融合前Fタンパク質。
- 前記組換え融合前Fタンパク質は、前記安定化変異の内の3つ以上を含む、請求項1~9のいずれか一項に記載の組換え融合前Fタンパク質。
- 前記組換え融合前Fタンパク質は、前記安定化変異の内の3つ以上を含む、請求項1~9のいずれか一項に記載の組換え融合前Fタンパク質。
- 前記組換え融合前Fタンパク質は、前記安定化変異の内の4つ以上を含む、請求項1~9のいずれか一項に記載の組換え融合前Fタンパク質。
- 前記組換え融合前Fタンパク質は、前記安定化変異の内の5つ以上を含む、請求項1~9のいずれか一項に記載の組換え融合前Fタンパク質。
- 前記組換え融合前Fタンパク質は、前記安定化変異の内の6つ以上を含む、請求項1~9のいずれか一項に記載の組換え融合前Fタンパク質。
- 前記タンパク質は、前記融合前コンフォメーションFタンパク質に特異的な少なくとも1つのエピトープを含み、前記少なくとも1つのエピトープは、配列番号1の重鎖CDR1領域、配列番号2の重鎖CDR2領域、配列番号3の重鎖CDR3領域、並びに配列番号4の軽鎖CDR1領域、配列番号5の軽鎖CDR2領域、及び配列番号6の軽鎖CDR3領域を含む融合前特異的モノクローナル抗体並びに/又は配列番号7の重鎖CDR1領域、配列番号8の重鎖CDR2領域、配列番号9の重鎖CDR3領域、並びに配列番号10の軽鎖CDR1領域、配列番号67の軽鎖CDR2領域、及び配列番号11の軽鎖CDR3領域を含む融合前特異的モノクローナル抗体により認識される、請求項1~15のいずれか一項に記載の融合前RSV Fタンパク質。
- 前記タンパク質は、三量体である、請求項1~16のいずれか一項に記載の融合前RSV Fタンパク質。
- 短縮されたF1ドメイン、及び前記短縮されたF1ドメインに結合した異種三量化ドメインを含む請求項1~17のいずれか一項に記載の融合前RSV Fタンパク質。
- 前記異種三量化ドメインは、アミノ酸配列GYIPEAPRDGQAYVRKDGEWVLLSTFL(配列番号15)を含む、請求項18に記載の融合前RSV Fタンパク質。
- 前記三量化ドメインは、前記RSV Fタンパク質のアミノ酸残基513に結合している、請求項18又は19に記載の融合前RSV Fタンパク質。
- 請求項1~20のいずれか一項に記載の融合前RSV Fタンパク質をコードする核酸分子。
- 前記核酸分子は、哺乳動物細胞における発現用にコドン最適化されている、請求項21に記載の核酸分子。
- 請求項21又は22に記載の核酸分子を含むベクター。
- 請求項1~20のいずれか一項に記載の融合前RSV Fタンパク質、請求項21若しくは22に記載の核酸分子、及び/又は請求項23に記載のベクターを含む組成物。
- RSV Fタンパク質に対する免疫応答の誘導での使用のための、請求項1~20のいずれか一項に記載の融合前RSV Fタンパク質、請求項21若しくは22に記載の核酸分子、及び/又は請求項23に記載のベクター。
- ワクチンとしての使用のための、請求項1~20のいずれか一項に記載の融合前RSV Fタンパク質、請求項21若しくは22に記載の核酸分子、及び/又は請求項23に記載のベクター。
- RSV感染の予防及び/又は処置での使用のための、請求項1~20のいずれか一項に記載の融合前RSV Fタンパク質、請求項21若しくは22に記載の核酸分子、及び/又は請求項23に記載のベクター。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18205863 | 2018-11-13 | ||
EP18205863.6 | 2018-11-13 | ||
PCT/EP2019/080989 WO2020099383A1 (en) | 2018-11-13 | 2019-11-12 | Stabilized pre-fusion rsv f proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022513025A true JP2022513025A (ja) | 2022-02-07 |
JPWO2020099383A5 JPWO2020099383A5 (ja) | 2022-11-11 |
Family
ID=64308587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021525874A Pending JP2022513025A (ja) | 2018-11-13 | 2019-11-12 | 安定化された融合前rsv fタンパク質 |
Country Status (19)
Country | Link |
---|---|
US (1) | US20220017574A1 (ja) |
EP (1) | EP3880243A1 (ja) |
JP (1) | JP2022513025A (ja) |
KR (1) | KR20210091749A (ja) |
CN (1) | CN113164583A (ja) |
AU (1) | AU2019377989A1 (ja) |
BR (1) | BR112021008975A2 (ja) |
CA (1) | CA3117275A1 (ja) |
CL (1) | CL2021001212A1 (ja) |
CO (1) | CO2021006308A2 (ja) |
CR (1) | CR20210306A (ja) |
EA (1) | EA202191355A1 (ja) |
EC (1) | ECSP21042554A (ja) |
IL (1) | IL282892A (ja) |
JO (1) | JOP20210106A1 (ja) |
MX (1) | MX2021005607A (ja) |
PE (1) | PE20211469A1 (ja) |
SG (1) | SG11202104522UA (ja) |
WO (1) | WO2020099383A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10456462B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Preventions B.V. | Vaccine against RSV |
WO2017174564A1 (en) | 2016-04-05 | 2017-10-12 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
PL3464331T3 (pl) | 2016-05-30 | 2021-04-19 | Janssen Vaccines & Prevention B.V. | Stabilizowane przedfuzyjne białka F RSV |
JP2024509756A (ja) * | 2021-02-19 | 2024-03-05 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 安定化された融合前rsv fb抗原 |
KR20230047033A (ko) * | 2021-09-29 | 2023-04-06 | 에스케이바이오사이언스(주) | 재조합된 약독화 rsv 생백신 및 이를 제조하는 방법 |
CN115850396B (zh) * | 2022-12-22 | 2024-02-06 | 北京吉诺卫生物科技有限公司 | 一种rsv纳米颗粒疫苗及其制备方法与应用 |
CN117304280B (zh) * | 2023-11-28 | 2024-04-16 | 江苏瑞科生物技术股份有限公司 | 一种重组rsv f蛋白及其应用 |
CN117304279B (zh) * | 2023-11-28 | 2024-04-16 | 江苏瑞科生物技术股份有限公司 | 一种重组rsv f蛋白及其应用 |
CN117777251B (zh) * | 2024-02-27 | 2024-06-04 | 普大生物科技(泰州)有限公司 | 一种rsv纳米颗粒疫苗及其制备方法 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
US20100261155A1 (en) * | 2007-06-06 | 2010-10-14 | Nationwide Children's Hospital, Inc. | Methods and compositions relating to viral fusion proteins |
EP3109258B1 (en) | 2007-12-24 | 2019-01-23 | ID Biomedical Corporation of Quebec | Recombinant rsv antigens |
DK2445526T3 (en) | 2009-06-24 | 2016-06-27 | Glaxosmithkline Biologicals Sa | Recombinant RSV antigens. |
EA201270062A1 (ru) | 2009-06-24 | 2013-02-28 | АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК | Вакцина |
CA2770737C (en) * | 2009-08-13 | 2020-05-12 | Crucell Holland B.V. | Antibodies against human respiratory syncytial virus (rsv) and methods of use |
NZ703035A (en) | 2010-07-09 | 2016-06-24 | Crucell Holland Bv | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
CA2835644C (en) | 2011-05-13 | 2021-06-15 | Novartis Ag | Pre-fusion rsv f antigens |
CN112851766A (zh) * | 2013-03-13 | 2021-05-28 | 美国政府(由卫生和人类服务部的部长所代表) | 融合前rsv f蛋白和其用途 |
EP2970981B1 (en) * | 2013-03-14 | 2020-10-28 | Emory University | Recombinant rsv with silent mutations, vaccines, and methods related thereto |
KR102236497B1 (ko) | 2013-04-25 | 2021-04-06 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 가용성 예비융합 rsv f 폴리펩타이드 |
AP2015008893A0 (en) * | 2013-06-17 | 2015-12-31 | Crucell Holland Bv | Stabilized soluble pre-fusion rsv f polypeptides |
WO2016040556A1 (en) * | 2014-09-12 | 2016-03-17 | Rsv Corporation | Virosomes containing respiratory syncytial virus strain line 19 fusion protein and uses thereof |
US10456462B2 (en) * | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Preventions B.V. | Vaccine against RSV |
CN107847581B (zh) * | 2015-07-07 | 2022-03-22 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
BR112018008708A2 (pt) * | 2015-10-29 | 2018-11-06 | Univ Emory | rsv quimérico, composições imunogênicas e métodos de uso |
CN108738312A (zh) * | 2015-12-23 | 2018-11-02 | 辉瑞公司 | Rsv f蛋白突变体 |
CN115960263A (zh) * | 2016-03-29 | 2023-04-14 | 美国政府(由卫生和人类服务部的部长所代表) | 取代修饰的融合前rsv f蛋白及其用途 |
PT3439672T (pt) | 2016-04-05 | 2021-02-24 | Janssen Vaccines & Prevention Bv | Proteína f do rsv pré-fusão solúvel e estabilizada para uso na profilaxia de infeção por rsv |
PL3464331T3 (pl) * | 2016-05-30 | 2021-04-19 | Janssen Vaccines & Prevention B.V. | Stabilizowane przedfuzyjne białka F RSV |
-
2019
- 2019-11-12 CN CN201980074164.XA patent/CN113164583A/zh active Pending
- 2019-11-12 CR CR20210306A patent/CR20210306A/es unknown
- 2019-11-12 AU AU2019377989A patent/AU2019377989A1/en active Pending
- 2019-11-12 EA EA202191355A patent/EA202191355A1/ru unknown
- 2019-11-12 CA CA3117275A patent/CA3117275A1/en active Pending
- 2019-11-12 WO PCT/EP2019/080989 patent/WO2020099383A1/en active Application Filing
- 2019-11-12 EP EP19798149.1A patent/EP3880243A1/en active Pending
- 2019-11-12 JP JP2021525874A patent/JP2022513025A/ja active Pending
- 2019-11-12 PE PE2021000680A patent/PE20211469A1/es unknown
- 2019-11-12 SG SG11202104522UA patent/SG11202104522UA/en unknown
- 2019-11-12 US US17/293,364 patent/US20220017574A1/en active Pending
- 2019-11-12 BR BR112021008975-6A patent/BR112021008975A2/pt unknown
- 2019-11-12 JO JOP/2021/0106A patent/JOP20210106A1/ar unknown
- 2019-11-12 MX MX2021005607A patent/MX2021005607A/es unknown
- 2019-11-12 KR KR1020217017491A patent/KR20210091749A/ko unknown
-
2021
- 2021-05-03 IL IL282892A patent/IL282892A/en unknown
- 2021-05-07 CL CL2021001212A patent/CL2021001212A1/es unknown
- 2021-05-13 CO CONC2021/0006308A patent/CO2021006308A2/es unknown
- 2021-06-11 EC ECSENADI202142554A patent/ECSP21042554A/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021008975A2 (pt) | 2021-08-17 |
EA202191355A1 (ru) | 2021-09-20 |
AU2019377989A1 (en) | 2023-10-05 |
CO2021006308A2 (es) | 2021-05-31 |
CN113164583A (zh) | 2021-07-23 |
IL282892A (en) | 2021-06-30 |
ECSP21042554A (es) | 2021-11-30 |
WO2020099383A1 (en) | 2020-05-22 |
KR20210091749A (ko) | 2021-07-22 |
EP3880243A1 (en) | 2021-09-22 |
CL2021001212A1 (es) | 2021-10-22 |
CA3117275A1 (en) | 2020-05-22 |
CR20210306A (es) | 2021-07-22 |
PE20211469A1 (es) | 2021-08-05 |
MX2021005607A (es) | 2021-06-30 |
SG11202104522UA (en) | 2021-05-28 |
US20220017574A1 (en) | 2022-01-20 |
JOP20210106A1 (ar) | 2023-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7238000B2 (ja) | 安定化された可溶性融合前rsv fポリペプチド | |
JP2022513025A (ja) | 安定化された融合前rsv fタンパク質 | |
TWI663175B (zh) | 穩定化可溶性融合前rsv f多肽 | |
JP7189014B2 (ja) | Rsvに対するワクチン | |
KR102506895B1 (ko) | 안정화된 용해성 융합-전 rsv f 단백질 | |
AU2021232702B2 (en) | Stabilized pre-fusion RSV F proteins | |
EA034653B1 (ru) | Стабилизированные растворимые f-полипептиды rsv перед слиянием | |
WO2017207477A1 (en) | Stabilized pre-fusion rsv f proteins | |
JP2024509756A (ja) | 安定化された融合前rsv fb抗原 | |
CN117460527A (zh) | 稳定化的融合前rsv fb抗原 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221101 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221101 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231023 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231031 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240131 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240327 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240514 |